The Pfizer-BioNTech Comirnaty Covid-19 vaccine has been approved for use as a booster dose in children aged 5 to 11 years old by Canada′s drug authority.

According to Health Canada, this booster dose is an effective way to regain protection for people in this age group, especially for those at a high risk of developing a severe illness.

In the meantime, on Friday, the National Advisory Committee on Immunization (NACI) issued national advice for its usage. NACI has advised a first booster dose of the 10 mcg vaccine should be given to children aged 5 to 11 who have an underlying medical condition that puts them at a high risk of developing serious illness from Covid-19, particularly children who are immunocompromised, at least six months after the end of a primary series. 

While for other children in the same age group, NACI advised the 10 mcg Comirnaty vaccines may be given as a first booster at least six months after the primary doses have been administered. (Times of India, Aug 20, 2022)